Open AccessEph receptors and ephrins as targets for cancer therapy
Author(s) -
Xi HongQing,
Wu XiaoSong,
Wei Bo,
Chen Lin
Publication year - 2012
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2012.01612.x
Subject(s) - erythropoietin producing hepatocellular (eph) receptor , ephrin , eph receptor a2 , receptor tyrosine kinase , receptor , cancer research , metastasis , biology , receptor protein tyrosine kinases , tyrosine kinase , cancer , bioinformatics , biochemistry , genetics
Eph receptor tyrosine kinases and their ephrin ligands are involved in various signalling pathways and mediate critical steps of a wide variety of physiological and pathological processes. Increasing experimental evidence demonstrates that both Eph receptor and ephrin ligands are overexpressed in a number of human tumours, and are associated with tumour growth, invasiveness and metastasis. In this regard, the Eph/ephrin system provides the foundation for potentially exciting new targets for anticancer therapies for Eph‐expressing tumours. The purpose of this review is to outline current advances in the role of Eph receptors and ephrin ligands in cancer, and to discuss novel therapeutic approaches of anticancer therapies.